SAN DIEGO--(BUSINESS WIRE)--Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced its randomized, controlled Phase 2/3 clinical trial, called Toca 5, is now enrolling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results